20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Omeros Corporation (NASDAQ:OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy.
- Treatment with narsoplimab showed a median reduction in proteinuria of 64.4%.
- The magnitude of median proteinuria reduction seen with narsoplimab is predicted to delay progression to renal dialysis by 41.6 years compared to the standard of care.
- 58% of patients received only one narsoplimab treatment course (12 weekly doses) or less annually, with 25% of patients showing improvement in eGFR despite having significant, longstanding IgA nephropathy with high-risk comorbidities.
- eGFR rate of decline was slowed by 3.4 mL/min/year compared to a literature control cohort with IgA nephropathy.
- Narsoplimab was well-tolerated with no treatment-related serious adverse events.
- Related Link: Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA.
- Price Action: OMER shares closed up 0.53% at $7.55 on Friday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!